Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
02/16/20178:08AMPRNUSU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review Second Successful BLA Filing of the Partnership in the U.S. PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India... More...>>
02/14/20171:59PMPRNUSMylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 14, 2017 HERTFORDSHIRE, England and PITTSBURGH, Feb. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today applauds the rebranding of the Generic Pharmaceutical... More...>>
02/03/20176:33AMPRNUSMylan to Host Investor Day on March 1, 2017 in New York City
Mylan to Host Investor Day on March 1, 2017 in New York City PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 3, 2017 HERTFORDSHIRE, England and PITTSBURGH, Feb. 3, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host an Investor Day on March 1, 2017 in New York City. Mylan CEO Heather... More...>>
02/01/20173:02AMDJNMore Headaches for Drugmakers -- WSJ
By Peter Loftus and Preetika Rana The U.S. pharmaceutical industry has been under pressure over high and rising drug prices. Now after criticism from the White House, it's feeling the heat for where it makes its products, too. "I want you to manufacture in the United States," President Donald Trump told... More...>>
01/30/20176:51PMPRNUSMylan Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents
Mylan Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 30, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 30, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the United States District Court for the District of Delaware... More...>>
01/19/20174:27PMDJNRival to EpiPen Allergy Treatment to Return to Market--Update
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/19/20173:17PMDJNRival to EpiPen Allergy Treatment to Return to Market
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/12/20175:03PMDJNCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
By Anne Steele and Joseph Walker A top U.S. health insurer has dropped its coverage of Mylan NV's brand-name EpiPen and switched to the half-priced version Mylan launched in response to public outrage over its sharp price increases on the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's... More...>>
01/12/201712:49PMDJNCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic
By Anne Steele A top U.S. health insurer has dropped its coverage of Mylan NV's EpiPen and switched to its generic alternative, following public outrage over sharp price increases for the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's half-priced generic version, according to... More...>>
01/11/20178:00AMPRNUSU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S. PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Jan. 11, 2017 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU... More...>>
01/09/20178:45AMPRNUSMylan to Present at the 35th Annual J.P. Morgan Healthcare Conference
Mylan to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that CEO Heather Bresch will present at the 35th Annual J.P. Morgan Healthcare... More...>>
01/09/20177:30AMPRNUSMylan Acquires Cold-EEZE® Brand to Further Expand OTC Business
Mylan Acquires Cold-EEZE® Brand to Further Expand OTC Business PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has agreed to acquire global rights to Cold-EEZE® brand cold remedy... More...>>
12/29/20164:23PMPRNUSMylan Launches Generic Concerta® Tablets
Mylan Launches Generic Concerta® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36... More...>>
12/29/20167:00AMPRNUSMylan Launches Generic Cerebyx® Injection
Mylan Launches Generic Cerebyx® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Fosphenytoin Sodium Injection USP, 75 mg/mL, (50 mg PE*/mL), packaged in 100... More...>>
12/28/20164:33PMPRNUSMylan Launches Generic Zovia® Tablets
Mylan Launches Generic Zovia® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1 mg / 0.05 mg. Mylan's... More...>>
12/27/20168:00AMPRNUSJournal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data
Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data HERITAGE Study Results Demonstrate Equivalent Overall Response Rate for MYL-1401O in Comparison to Branded Trastuzumab PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Dec... More...>>
12/16/20168:01AMPRNUSMylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic
Mylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic Authorized Generic Offered at More Than 50% Below Wholesale Acquisition Cost of EpiPen Auto-Injector PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec... More...>>
12/09/201610:50PMBWMYLAN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General & Kahn Swick & Foti, LLC Remin...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until December 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL). Investor... More...>>
12/05/20164:31PMPRNUSRosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadline in Class Action Filed by Firm - MYL
Rosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadline in Class Action Filed by Firm - MYL PR Newswire NEW YORK, Dec. 5, 2016 NEW YORK, Dec. 5, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Mylan Inc., predecessor of Mylan N.V., and/or... More...>>
12/01/20161:34PMBWThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mylan NV Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mylan N.V. (“Mylan” or the “Company”) (NASDAQ: MYL) securities between February 28, 2013 and October 7, 2016, inclusive (the “Class Period”). Mylan investors have until December 12, 2016 to... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170227 04:44:35